Thermo Fisher Scientific Inc. (TMO) Free Cash Flow CAGR:-5.81%(TTM)
The free cash flow cagr for Thermo Fisher Scientific Inc. (TMO) is -5.81% over the latest trailing 12-month period. Free cash flow CAGR uses precomputed cash-flow statement history.
The free cash flow cagr for Thermo Fisher Scientific Inc. (TMO) stock is -5.81% over the past 12 months. The 3 year average growth rate is -0.73% and the 5 year cagr is -0.19%. Free cash flow CAGR measures how Thermo Fisher Scientific Inc.'s cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
TMO Free Cash Flow CAGR Chart
Thermo Fisher Scientific Inc. (TMO)
TMO Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $7.27B | $6.29B | $-974.00M | -13.40% | -13.40% |
| 2024 | $6.93B | $7.27B | +$340.00M | +4.91% | +4.91% |
| 2023 | $6.91B | $6.93B | +$16.00M | +0.23% | +0.23% |
| 2022 | $7.02B | $6.91B | $-109.00M | -1.55% | -1.55% |
| 2021 | $6.82B | $7.02B | +$205.00M | +3.01% | +3.01% |
| 2020 | $4.05B | $6.82B | +$2.77B | +68.40% | +68.40% |
| 2019 | $3.79B | $4.05B | +$262.00M | +6.92% | +6.92% |
| 2018 | $3.50B | $3.79B | +$288.00M | +8.24% | +8.24% |
| 2017 | $2.71B | $3.50B | +$785.10M | +28.95% | +28.95% |
| 2016 | $2.39B | $2.71B | +$317.90M | +13.28% | +13.28% |
| 2015 | $2.19B | $2.39B | +$202.00M | +9.22% | +9.22% |
| 2014 | $1.73B | $2.19B | +$463.70M | +26.83% | +26.83% |
| 2013 | $1.72B | $1.73B | +$3.90M | +0.23% | +0.23% |
| 2012 | $1.42B | $1.72B | +$299.90M | +21.05% | +21.05% |
| 2011 | $1.23B | $1.42B | +$192.20M | +15.60% | +15.60% |
| 2010 | $1.45B | $1.23B | $-219.40M | -15.11% | -15.11% |
| 2009 | $1.16B | $1.45B | +$295.90M | +25.60% | +25.60% |
| 2008 | $1.31B | $1.16B | $-152.20M | -11.64% | -11.64% |
| 2007 | $328.86M | $1.31B | +$979.14M | +297.74% | +297.74% |
| 2006 | $227.37M | $328.86M | +$101.49M | +44.64% | +44.64% |
| 2005 | $214.53M | $227.37M | +$12.84M | +5.99% | +5.99% |
| 2004 | $170.58M | $214.53M | +$43.94M | +25.76% | +25.76% |
| 2003 | $51.68M | $170.58M | +$118.90M | +230.08% | +230.08% |
| 2002 | $103.60M | $51.68M | $-51.92M | -50.12% | -50.12% |
| 2001 | $125.88M | $103.60M | $-22.28M | -17.70% | -17.70% |
| 2000 | $-150.88M | $125.88M | +$276.76M | +0.00% | N/A |
| 1999 | $-72.70M | $-150.88M | $-78.18M | +0.00% | N/A |
| 1998 | $-691.70M | $-72.70M | +$619.00M | +0.00% | N/A |
| 1997 | $100.00M | $-691.70M | $-791.70M | -791.70% | N/A |
Quarterly Free Cash Flow — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $816.00M | -72.7% | +126.0% |
| Q4 2025 | $2.99B | +63.1% | +6.5% |
| Q3 2025 | $1.83B | +66.1% | -3.1% |
| Q2 2025 | $1.10B | +206.1% | -33.4% |
| Q1 2025 | $361.00M | -87.2% | -60.1% |
| Q4 2024 | $2.81B | +48.4% | -15.3% |
| Q3 2024 | $1.89B | +14.2% | -9.0% |
| Q2 2024 | $1.66B | +83.5% | +32.1% |
| Q1 2024 | $904.00M | -72.8% | +233.6% |
| Q4 2023 | $3.32B | +59.4% | +13.0% |
| Q3 2023 | $2.08B | +65.8% | +49.8% |
| Q2 2023 | $1.26B | +363.5% | +22.9% |
| Q1 2023 | $271.00M | -90.8% | -82.7% |
| Q4 2022 | $2.94B | +111.3% | +58.2% |
| Q3 2022 | $1.39B | +36.0% | -34.6% |
| Q2 2022 | $1.02B | -34.6% | -39.4% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Marc N. Casper